mSphere · 2022
PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Simon Viviana, Kota Vamsi, Bloomquist Ryan F, Hanley Hannah B, Forgacs David, Pahwa Savita, Pallikkuth Suresh, Miller Loren G, Schaenman Joanna, Yeaman Michael R, Manthei David, Wolf Joshua, Gaur Aditya H, Estepp Jeremie H, Srivastava Komal, Carreño Juan Manuel, Cuevas Frans, PARIS/SPARTA Study Group,, Ellebedy Ali H, Gordon Aubree, Valdez Riccardo, Cobey Sarah, Reed Elaine F, Kolhe Ravindra, Thomas Paul G, Schultz-Cherry Stacey, Ross Ted M, Krammer Florian
Аннотация
To understand reinfection rates and correlates of protection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we established eight different longitudinal cohorts in 2020 under the umbrella of the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2)/SPARTA (SARS SeroPrevalence And Respiratory Tract Assessment) studies. Here, we describe the PARIS/SPARTA cohorts, the harmonized assays and analysis that are performed across the cohorts, as well as case definitions for SARS-CoV-2 infection and reinfection that have been established by the team of PARIS/SPARTA investigators. IMPORTANCE Determining reinfection rates and correlates of protection against SARS-CoV-2 infection induced by both natural infection and vaccination is of high significance for the prevention and control of coronavirus disease 2019 (COVID-19). Furthermore, understanding reinfections or infection after vaccination and the role immune escape plays in these scenarios will inform the need for updates of the current SARS-CoV-2 vaccines and help update guidelines suitable for the postpandemic world.